07:00 , Aug 6, 2007 |  BC Week In Review  |  Company News

Compugen board of directors update

Compugen Ltd. (CGEN), Tel Aviv, Israel   Business: Gene/Cell therapy, Diagnostic, Computational chemistry/biology   Appointed: Yair Aharonowitz, professor of microbiology and biotechnology at Tel Aviv University ; Arie Ovadia, a financial advisor; and Joshua Shemer,...
08:00 , Mar 28, 2005 |  BC Week In Review  |  Company News

Berna, Mega Pharma S.A. deal

Mega Pharma acquired BBIN's Rhein Immuno BV generics unit (Buenos Aires, Argentina) for an undisclosed sum. The unit is part of Rhein Biotech N.V., which BBIN acquired in 2002. Berna Biotech Ltd. (SWX:BBIN), Berne, Switzerland...
08:00 , Jan 13, 2003 |  BioCentury  |  Finance

Europe's dilemma

Peering into 2003, European equity markets for biotech look muted, as the flight of institutional capital to the U.S. continues apace, and European biobanking scales back from its expansion binge during the retail-driven genomics bubble....
07:00 , Jul 29, 2002 |  BC Week In Review  |  Company News

Berna, Rhein deal

BBIN completed its previously-announced acquisition of RBO for cash and stock (see BioCentury, May 28). Berna Biotech Ltd. (SWX:BBIN), Berne, Switzerland   Rhein Biotech N.V. (NMarkt:RBO), Maastricht, the Netherlands   Business: Infectious diseases  ...
07:00 , Jul 1, 2002 |  BC Week In Review  |  Company News

Berna, Rhein deal

BBIN launched its tender offer to acquire all the outstanding shares of RBO. RBO shareholders will receive 1.42 BBIN shares plus EUR 33.75 ($32.77) in cash per RBO share. Green Cross Corp , RBO's largest...
07:00 , Jul 1, 2002 |  BioCentury  |  Finance

Europe: Less of a cash crunch

2Q Financial Markets Review Europe: Less of a cash crunch The first six months of 2002 have ended with no sign of an IPO or follow-on window, and an increasingly cautious venture community. In Europe,...
07:00 , Jun 10, 2002 |  BioCentury  |  Finance

More European M & A

For the third week running, European companies did a bit of consolidating. Danish cancer play TopoTarget A/Sand U.K. cancer play Prolifix Ltd. said they will merge in a cash and stock transaction. The move follows...
07:00 , May 28, 2002 |  BC Week In Review  |  Company News

Berna, Rhein deal

BBIN will acquire RBO for E279 million ($257 million). BBIN will offer 1.42 shares plus E33.75 in cash for every RBO share, valuing RBO at E68.50 per share, a 29% premium to RBO's close at...
07:00 , May 28, 2002 |  BioCentury  |  Strategy

Building bulk in vaccines

The acquisition of profitable vaccine company Rhein Biotech N.V. by Berna Biotech AG will create Europe's sixth largest biotech company with a market cap in the region of E820 million ($755 million). Last week's deal...
07:00 , Apr 15, 2002 |  BC Week In Review  |  Company News

Corixa, Rhein deal

RBO obtained co-exclusive marketing rights to CRXA's RC-529 synthetic adjuvant for use with its prophylactic two-dose hepatitis B vaccine and therapeutic hepatitis B vaccine. CRXA, which will supply RBO with the adjuvant, will receive upfront...